$3.35
-0.26 (-7.08%)
Open$3.46
Previous Close$3.60
Day High$3.46
Day Low$3.11
52W High$28.03
52W Low$1.83
Volume—
Avg Volume10.1K
Market Cap17.69M
P/E Ratio—
EPS$-5.27
SectorBiotechnology
Analyst Ratings
Strong Sell
6 analysts
Price Target
+1,112.9% upside
Current
$3.35
$3.35
Target
$40.57
$40.57
$36.99
$40.57 avg
$64.99
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 5.39M | 5.45M | 4.30M |
| Net Income | -1,299,864 | -1,279,500 | -760,803 |
| Profit Margin | -24.1% | -23.5% | -17.7% |
| EBITDA | -1,608,718 | -1,854,994 | -1,475,925 |
| Free Cash Flow | -1,268,218 | -1,023,573 | -724,682 |
| Rev Growth | -8.0% | -5.0% | +17.9% |
| Debt/Equity | 0.74 | 0.71 | 0.67 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $249.46 | -0.54% | 118.6 | 430.95B |
| AMGN | Amgen Inc | $415.21 | -0.63% | 25.1 | 219.39B |
| GILD | Gilead Sciences Inc | $138.36 | +0.16% | — | 165.85B |
| VRTX | Vertex Pharmaceuticals Inc | $505.75 | -2.07% | 28.3 | 124.51B |
| REGN | Regeneron Pharmaceuticals | $803.48 | -0.31% | 18.4 | 79.53B |
| ALNY | Alnylam Pharmaceuticals Inc | $228.65 | +0.67% | 35.2 | 28.41B |